Business Context and Reporting Period
Foresight Acquisition Corp., a special purpose acquisition company, reported on May 25, 2021 that it entered into definitive agreements to combine with P3 Health Group Holdings, LLC, the operating entity associated with P3 Health Partners. The filing is a transaction update rather than a periodic financial report; it does not provide a clear operating reporting period for P3.
The proposed transaction would create an Up-C structure. Foresight would own approximately 30% of the surviving company, become its sole manager, and rename and recapitalize itself at closing. The filing was signed June 1, 2021, although the reported transaction date was May 25, 2021.
Key Financial and Transaction Metrics
- Implied merger consideration: $2.126 billion.
- Equity consideration: 181,104,693 surviving-company common units, valued at $10 per unit, assuming no Foresight share redemptions and $208.7 million of PIPE proceeds.
- Cash consideration: $314.953 million, subject to adjustment if post-closing net cash from Foresight and the surviving company, excluding P3 and subsidiary cash, is below $180 million.
- PIPE financing: 20,870,307 Foresight Class A shares at $10 per share, for aggregate proceeds of $208.703 million, subject to customary closing conditions.
- Minimum available cash condition: at least $400 million after transaction expenses, redemptions, PIPE issuance and other permitted securities issuances.
- Operating metrics: the filing does not provide clear values for revenue, net income, EBITDA, cash flow, margins, debt, or liquidity beyond the transaction-specific cash thresholds described above.
Material Changes Versus the Prior Comparable Period
No comparable-period financial results are presented, so the filing does not establish changes in revenue, profitability, cash flow, leverage, margins, or liquidity versus a prior period.
The material development is the execution of the merger and related blocker agreements, together with the planned PIPE financing and proposed conversion of Foresight into the post-combination public company.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
- Closing is subject to Foresight stockholder approval, required regulatory and Hart-Scott-Rodino filings, other merger approvals, satisfaction of the minimum available cash condition, and customary accuracy of representations and warranties.
- The transaction was expected to close by November 21, 2021, subject to an automatic 90-day extension in certain circumstances related to the SEC warrant-accounting matter.
- Foresight planned to conduct a warrant exchange offer or solicitation to exchange warrants for Class A common stock or cash and/or amend the warrant terms.
- P3 unitholders could elect additional surviving-company common units instead of cash consideration. Following closing, non-Foresight holders could generally exchange one surviving-company unit and one Class V voting share for either one Foresight Class A share or cash, at Foresight’s option.
- The transaction includes a tax receivable agreement, registration rights, and lock-up provisions. P3 holder shares were generally subject to a six-month lock-up, while sponsor shares were generally subject to a one-year lock-up, subject to specified early-release conditions.
- Foresight’s sponsor agreed to support the transaction, vote in favor of the proposals, and tender its Foresight warrants in the contemplated warrant offer.
- Termination rights include failure to close by the outside date, failure to obtain stockholder approval, regulatory prohibitions, specified breaches, and issues involving P3’s PCAOB-audited or 2020 audited financial statements. A $5 million termination fee could be payable by Foresight in specified superior-proposal circumstances.
- Principal risks include redemption levels, financing availability, regulatory or stockholder approval, delays in audited financial statements or proxy materials, uncertain projected P3 financial information, competition, growth execution, litigation or investigations, and failure to realize expected transaction benefits.
Important Facts for Investors to Verify
- Whether Foresight stockholders approved the transaction and whether the merger ultimately closed.
- Actual redemptions, PIPE proceeds, available cash, and the final mix of cash and equity consideration.
- P3’s audited financial statements, including whether they differed materially from previously provided unaudited 2020 results.
- P3’s actual revenue, profitability, cash flow, debt, liquidity, and operating performance, which are not provided in this filing.
- Final ownership percentages, share and unit counts, warrant treatment, and dilution following the transaction.
- Terms and future payment obligations under the tax receivable agreement and other transaction agreements.
- Subsequent proxy filings, warrant-offer documents, registration statements, and disclosures regarding regulatory, litigation, or accounting developments.